CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SUCCIPRO is a drug development company focused on creating therapies that target the succinate-SUCNR1 pathway, particularly for inflammatory and metabolic disorders. Their lead product, SUCZYME, is an oral enzyme therapy aimed at treating Crohn's Disease and is currently in the early stages of clinical development.
SUCCIPRO is a spin-off company from Pere Virgili Health Institute and Rovira Virgili University.
It is an early-stage drug development company focused on therapies able to modulate the succinate-SUCNR1 pathway, which have strong potential on many inflammatory and metabolic disorders.
Currently, the company is developing SUCZYME, a novel first-in-class oral enzyme therapy able to deplete succinate that has Crohn's Disease as a first indication. SUCCIPRO will lead the development until the end of…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
